Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go:
Expired
investment:
Withheld
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go:
Expired
investment:
£1,310,090
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go:
Expired
investment:
£1,149,999
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their health where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go:
Expired
investment:
£737,480
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go:
Expired
investment:
£262,500
Cell Guidance Systems is developing a technology called PODS (Polyhedrin Delivery System) PODS allow them to deliver therapeutic proteins accurately and over long periods of time. PODS enable proteins to treat diseases, such as Parkinson’s disease and osteoarthritis.
days to go:
Expired
investment:
£836,370
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.
days to go:
Expired
investment:
£152,000
Africa New Energies holds an oil exploration license in Namibia, where it has applied its unique surface exploration method to identify a gross unrisked prospective resource of 1.6 billion barrels of oil equivalent.
days to go:
Expired
investment:
Withheld
Go Modular design and build off-site modules for the construction industry. Using their innovative modular construction technology they aim to revolutionise the construction process making it more time efficient and less expensive to produce buildings. In 2018, Go Modular are looking to open their first factory in the UK which will enable them to offer the construction industry factory-produced building units that form the finished structure at the construction site.
days to go:
Expired
investment:
£412,420
